YD Bio (YDES) Assets (2024 - 2025)
YD Bio (YDES) posted quarterly Assets of $13.8 million for Q4 2025, up 100.74% year-over-year from $6.9 million in Q4 2024, and up 135.9% quarter-over-quarter from $5.8 million in Q2 2025.
YD Bio (YDES) Assets (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Assets for 2 consecutive years, with $13.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets rose 100.74% year-over-year to $13.8 million; the TTM figure through Dec 2025 stood at $13.8 million (up 100.74% YoY), while the FY2025 annual figure was $13.8 million, up 100.74% from the prior year.
- Assets grew to $13.8 million in Q4 2025 per YDES's latest filing, from $5.8 million in the prior quarter.
- Across five years, Assets topped out at $13.8 million in Q4 2025 and bottomed at $5.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 19.82 Bn |
| 10 | YD Bio | 316.92 Mn | 310.91 Mn | - | 13.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.78 Mn |
| Jun 30, 2025 | 5.84 Mn |
| Dec 31, 2024 | 6.86 Mn |